A disturbing trend has emerged in the United States, with a rare vomiting syndrome linked to cannabis use on the rise. This condition, known as cannabinoid hyperemesis syndrome (CHS), is causing concern among medical professionals and researchers alike.
CHS is characterized by severe and recurring episodes of nausea, abdominal pain, and vomiting, impacting individuals who use cannabis regularly. What's intriguing is that this syndrome was only first reported in the US in 2009, and until recently, it didn't even have a dedicated diagnostic code, making it difficult to track.
Here's where it gets controversial... While CHS is still considered rare, the number of emergency room visits related to this condition has been steadily increasing. Researchers from the University of Illinois Chicago found that between 2016 and 2022, CHS visits to emergency departments rose significantly, from around 4 visits per 100,000 people to a staggering 22 visits per 100,000.
And this is the part most people miss... Despite the rise in cases, there's still much we don't know about CHS. For instance, why does it affect only a small proportion of cannabis users? And why does it seem to be more prevalent among younger individuals?
The syndrome typically develops gradually over the first few years of cannabis use, with morning nausea or abdominal pain being early indicators. As the condition progresses, individuals experience intense and recurrent vomiting and nausea for a day or two after cannabis use. Strangely, a hot bath or shower can sometimes provide temporary relief from these horrible symptoms.
The good news is that halting cannabis use can resolve CHS. However, during the COVID-19 pandemic, researchers James Swartz and Dana Franceschini found a significant increase in CHS cases in US emergency departments. Their research analyzed over 806 million ER visits nationwide and suggested that the pandemic's stress, isolation, and increased cannabis use may have contributed to this rise.
But here's the catch... Other researchers argue that the increase in diagnoses might not be solely due to increased cannabis use. It could also be attributed to a greater awareness and recognition of CHS, leading to more accurate diagnoses. In the past, CHS has often been misdiagnosed as cyclical vomiting syndrome, which is treated differently. This highlights the importance of asking the right questions and considering cannabis use as a potential factor.
So, what's the real story behind the rise in CHS cases? Is it a result of more people using cannabis frequently, or is it a case of improved awareness and diagnostics? Swartz and Franceschini suggest it could be a combination of both, with increased exposure to cannabis and heightened diagnostic vigilance post-2020.
Better diagnostics and further research are essential to truly understand the rarity of CHS and its impact on public health. The study by Swartz and Franceschini was published in JAMA Network Open, shedding light on this intriguing and often misunderstood syndrome.
